News Vertex's Orkambi CF drug okayed for funding in Australia Committee recommends outcomes-based deal
News Spark shares tank after haemophilia gene therapy safety sign... Biotech still pressing on with late stage trials
Partner Content Partner Content How challenges like Brexit & insufficient patients hinde... Challenges facing Orphan Drugs & Rare Diseases Research
Events Partner Content Orphan Drugs & Rare Diseases 2018 Orphan Drugs & Rare Diseases 2018 Conference
News NHS does not value CF patients, says Vertex CEO in letter to... But Vertex dismisses rumours it will quit the UK
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
